[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Sun Jing\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":68},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100543501","phase-2-a-clinical-study-on-the-efficacy-and-safety-of-paclitaxel-polymeric-micelles-and-cisplatin-combined-with-cadonilimab-as-a-neoadjuvant-therapy-for-locally-advanced-esophageal-squamous-cell-carcinoma-100543501",false,"NCT06356688","A Clinical Study on the Efficacy and Safety of Paclitaxel Polymeric Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma","A Clinical Study on the Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Single-Arm, Single-Center, Prospective Clinical Trial (POINTS Trial)","Inclusion Criteria:\n\n1. Age ≥18 years, ≤75 years, gender is not limited;\n2. Squamous esophageal cancer of thoracic segment confirmed by pathology;\n3. Locally advanced patients with no distant metastasis by imaging, resectable or potentially resectable after discussion among oncology, esophageal surgery, and imaging, and clinical stage cT2-4aN+ or cT3-4aN0, M0, stage II, III, or IVA (AJCC 8th edition cTNM staging);\n4. ECOG PS score of 0-1;\n5. No previous antitumor treatment such as radiotherapy, chemotherapy and immunotherapy;\n6. Expected survival \\> 6 months;\n7. Adequate baseline organ function: (i) WBC ≥3×10\\^9\u002FL, ANC ≥1.5×10\\^9\u002FL, PLT ≥100×10\\^9\u002FL, Hb ≥9g\u002FdL; (ii) Liver function: TBIL ≤2ULN, AST ≤2.5ULN, ALT ≤2.5ULN; (iii) Renal function: cCr\\>40 ml\u002Fmin, Cr≤1.5 ULN; (iv) Cardiac function: no cardiac disease or coronary artery disease. Cardiac function: no heart disease or coronary heart disease, patients with cardiac function grade 1-2;\n8. Hypertensive patients applying antihypertensive drugs to control blood pressure within the normal range;\n9. Diabetic patients with fasting blood glucose controlled at ≤8mmol\u002FL by hypoglycemic drug treatment;\n10. No other serious diseases (such as autoimmune diseases, immunodeficiency, organ transplantation, or other diseases that require continuous hormone therapy) that conflict with this protocol;\n11. No history of other malignant tumors;\n12. The patient agrees to participate in this clinical study and signs the Informed Consent Form.\n\nExclusion Criteria:\n\n1. Patients who have previously received anti-tumor therapy (including chemotherapy, radiotherapy, surgery or immunotherapy, etc.);\n2. Combination of other incurable malignant tumors (except cured non-malignant skin tumors, cervical cancer in situ, and prostate cancer);\n3. Patient has or anticipates a significant risk of esophageal perforation, fistula, and hemorrhage;\n4. Active autoimmune or immunodeficiency disease, use of immunosuppressants prior to enrollment, and use of immunosuppressant dosage ≥10 mg\u002Fday of oral prednisone for more than 2 weeks;\n5. Clinically significant cardiovascular disease including, but not limited to, severe acute myocardial infarction, unstable or severe angina pectoris, coronary artery bypass grafting surgery, congestive heart failure, ventricular arrhythmia requiring medical intervention, left ventricular ejection fraction \\\u003C50%, or other anticipated inability to tolerate chemoradiotherapy in the 6 months prior to enrollment;\n6. Severe allergies;\n7. Pregnant or lactating women;\n8. Severe mental disorders;\n9. Presence of CTC grade ≥3 peripheral nerve disease;\n10. Abnormal coagulation function (PT \\> 16s, APTT \\> 53s, TT \\> 21s, Fib \\\u003C 1.5g\u002FL), bleeding tendency or undergoing thrombolytic or anticoagulant therapy;\n11. Presence of severe pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, severe impairment of lung function, or active tuberculosis within 1 year;\n12. Presence of active hepatitis B or C;\n13. Any other condition that the investigator evaluates to be ineligible for enrollment.","ALL","18 Years","75 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The purpose of this study is to investigate the efficacy and safety of neoadjuvant treatment of locally advanced esophageal squamous carcinoma with a PD-1\u002FCTLA-4 bispecific antibody (Cadonilimab) in combination with platinum-containing chemotherapy (Paclitaxel Polymeric Micelles for Injection combined with Cisplatin). Includes pathologic complete remission rates (pCR rates) after 2-4 cycles of Cadonilimab combination chemotherapy. The objective remission rate (ORR), major pathologic remission rate (MPR), R0 resection rate and 2-year overall survival (OS) and progression-free survival (OS) rates, and safety of neoadjuvant treatment of locally advanced esophageal squamous carcinoma with Cadonilimab combined with chemotherapy.",[27,28],"Locally Advanced Esophageal Squamous Cell Carcinoma","Neoadjuvant Therapy",[30,31,32,33],"cadonilimab","neoadjuvant therapy","esophageal squamous cell carcinoma","Paclitaxel Polymeric Micelles for Injection","RECRUITING","2025-08-05",{"date":37,"type":38},"2025-08-08","ACTUAL",{"date":40,"type":38},"2025-04-20",{"date":42,"type":21},"2027-10-01",{"name":44,"class":45},"Sun Jing","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":63,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":67,"locationsCount":46},"100543503","phase-2-nocardia-rubra-cell-wall-skeleton-in-combination-with-prior-second--or-third-line-regimens-for-the-treatment-of-potentially-hazardous-colorectal-cancer-sd-status-100543503","NCT06356714","Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens for the Treatment of Potentially Hazardous Colorectal Cancer SD Status","An Open Intervention Study of Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens for the Treatment of Potentially Hazardous Colorectal Cancer SD(Stable Disease) Status","Inclusion Criteria:\n\n1. Age ≥ 18 years old, gender is not limited;\n2. Colorectal adenocarcinoma confirmed by pathologic histology and\u002For cytology and imaging;\n3. Have 1 or more measurable lesions with a longest diameter of at least 10 mm as determined by spiral CT scanning; and a diameter of at least 20 mm as determined by conventional CT scanning (Criteria for the Evaluation of Efficacy in Solid Tumors, i.e., RECIST Criteria, version 1.1);\n4. Prior second- or third-line therapy for advanced or metastatic colorectal cancer with potentially harmful SD status. The potentially hazardous SD (Stable Disease) state is defined as an increase in SLD (Sum of Longest Diameters) by less than 20% according to RECIST 1.1 criteria, with an absolute increase of SLD ≤ 5mm from the nadir; a serum CEA (Carcinoembryonic Antigen) level below 10.0 ng\u002Fml during stable disease, with two consecutive measurements of 10 ng\u002Fml or more (with a testing interval of at least one month); or a serum CEA level of 10 ng\u002Fml or more during stable disease, with a gradual increase in CEA after two consecutive measurements (with a testing interval of at least one month); a serum CA19-9 level below 60.0 ng\u002Fml during stable disease, with two consecutive measurements of 60 ng\u002Fml or more (with a testing interval of at least one month); or a serum CEA level of 60 ng\u002Fml or more during stable disease, with a gradual increase in CEA after two consecutive measurements (with a testing interval of at least one month). Meeting any one of the above criteria can be considered as the presence of a potentially hazardous SD state.\n5. The general condition score of the Eastern Cooperative Oncology Group (ECOG) is 0 or 1;\n6. Expected survival ≧3 months;\n7. Blood, liver and kidney function within 7 days prior to screening: absolute neutrophil count ≥ 1.5 x 109 \u002FL; hemoglobin ≥ 9.0 g\u002Fdl; platelet count ≥ 100 x 109 \u002FL; total bilirubin ≤ 1.5 times the upper limit of normal (ULN); gammaglutaminase and gammaglutaminase ≤ 3.0 x ULN (≤ 5 x ULN for patients with hepatic metastases); alkaline phosphatase ≤ 3 x ULN. phosphatase ≤ 3 x ULN (≤ 5 x ULN in patients with liver metastases); serum creatinine ≤ 1.5 x ULN;\n8. Agreed to sign the informed consent form;\n\nExclusion Criteria:\n\n1. Allergic constitution;\n2. With comorbid diabetes;\n3. Active clinically severe infection;\n4. Any other conditions deemed exclusionary by the investigator.",{"count":55,"type":21},22,[24],"Evaluate the efficacy and safety of Nocardia rubra cell wall skeleton in combination with prior second- or third-line regimens for the treatment of potentially hazardous colorectal cancer SD(Stable Disease) status in the real world.",[59,60],"Colorectal Cancer","Colorectal Neoplasms",[62,59,60],"Nocardia Rubra Cell Wall Skeleton",{"date":37,"type":38},{"date":65,"type":38},"2025-03-15",{"date":42,"type":21},{"name":44,"class":45},""]